10.40

1.28% -0.0928

Replimune Group Inc (REPL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$10.49

Offen:

$10.35

24-Stunden-Volumen:

134.52K

Relative Volume:

0.03

Marktkapitalisierung:

$815.30M

Einnahmen:

Nettoeinkommen (Verlust:

$-209.96M

KGV:

-3.2918

EPS:

-3.16

Netto-Cashflow:

$-176.27M

1W Leistung:

+3.61%

1M Leistung:

+20.76%

6M Leistung:

+6.27%

1J Leistung:

-20.61%

1-Tages-Spanne:

$10.27

$10.53

1-Wochen-Bereich:

$9.35

$11.26

52-Wochen-Spanne:

$2.68

$14.80

Replimune Group Inc Stock (REPL) Company Profile

Firmenname

Replimune Group Inc

Sektor

Healthcare (1136)

Branche

Biotechnology (632)

Telefon

(781) 222-9600

Adresse

500 UNICORN PARK, WOBURN, MA

Mitarbeiter

479

Twitter

@Replimune

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

REPL's Discussions on Twitter

Vergleichen Sie REPL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REPL Replimune Group Inc	10.39	826.01M	0	-209.96M	-176.27M	-3.16
VRTX Vertex Pharmaceuticals Inc	458.70	116.04B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	729.43	75.97B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	462.33	61.48B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	904.45	56.40B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	204.81	43.73B	447.02M	-1.18B	-906.14M	-6.1812

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-03	Hochstufung	BMO Capital Markets	Underperform → Market Perform
2025-10-27	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-10-20	Hochstufung	JP Morgan	Underweight → Neutral
2025-10-20	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-10-20	Hochstufung	Piper Sandler	Neutral → Overweight
2025-10-20	Hochstufung	Wedbush	Neutral → Outperform
2025-09-19	Herabstufung	JP Morgan	Neutral → Underweight
2025-07-30	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-07-23	Herabstufung	BMO Capital Markets	Outperform → Underperform
2025-07-23	Herabstufung	Barclays	Overweight → Equal Weight
2025-07-23	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-07-22	Herabstufung	JP Morgan	Overweight → Neutral
2025-07-22	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-07-22	Herabstufung	Piper Sandler	Overweight → Neutral
2025-07-22	Herabstufung	Wedbush	Outperform → Neutral
2025-06-20	Eingeleitet	Cantor Fitzgerald	Overweight
2024-08-28	Eingeleitet	ROTH MKM	Buy
2023-04-17	Fortgesetzt	Piper Sandler	Overweight
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-10-15	Fortgesetzt	BTIG Research	Buy
2020-11-17	Eingeleitet	BTIG Research	Buy
2020-11-02	Eingeleitet	Jefferies	Buy
2020-10-15	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-07-01	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-05-05	Eingeleitet	Barclays	Overweight
2019-09-04	Eingeleitet	ROTH Capital	Buy
2019-07-23	Eingeleitet	Chardan Capital Markets	Buy
2019-07-12	Hochstufung	JP Morgan	Neutral → Overweight
2019-07-08	Eingeleitet	H.C. Wainwright	Buy
2019-04-25	Eingeleitet	Wedbush	Outperform
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-08-14	Eingeleitet	JP Morgan	Overweight
2018-08-14	Eingeleitet	Leerink Partners	Outperform

Alle ansehen

Replimune Group Inc Aktie (REPL) Neueste Nachrichten

07:50 AM

Saturn V Capital Management LP Takes $1.20 Million Position in Replimune Group, Inc. $REPL - MarketBeat

07:50 AM

Dec 01, 2025

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - The National Law Review

Dec 01, 2025

Levi & Korsinsky Helps Retail Investors SueWallSt Over Alleged Fraud by Replimune Group, Inc. - The National Law Review

Dec 01, 2025

Nov 27, 2025

Will Replimune Group Inc. stock reach all time highs in 2025Oil Prices & Risk Managed Investment Strategies - BỘ NỘI VỤ

Nov 27, 2025

Nov 26, 2025

How Replimune Group Inc. stock trades during market volatility2025 Geopolitical Influence & Short-Term High Return Ideas - BỘ NỘI VỤ

Nov 26, 2025

Nov 25, 2025

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma DrugHagens Berman (PR Newswire) - Aktiellt

Nov 25, 2025

Nov 22, 2025

What Is Driving Replimune Stock’s 98% Surge Today? - MSN

Nov 22, 2025

Nov 21, 2025

Can One97 Communications Limited Deliver Consistent Free Cash FlowsVolume Spike Alerts & Swing Trade Smarter With Data Insights - earlytimes.in

Nov 21, 2025

Replimune Group Inc. stock volume spike explainedWeekly Stock Analysis & Short-Term Trading Alerts - newser.com

Nov 21, 2025

Nov 20, 2025

How Replimune Group Inc. stock reacts to global recession fearsMarket Trend Review & Smart Investment Allocation Insights - newser.com

Nov 20, 2025

Will Replimune Group Inc. stock deliver shareholder valueQuarterly Trade Summary & Weekly Watchlist for Consistent Profits - newser.com

Nov 20, 2025

Using AI based signals to follow Replimune Group Inc.Bond Market & Long Hold Capital Preservation Tips - newser.com

Nov 20, 2025

Nov 19, 2025

Trend analysis for Replimune Group Inc. this weekWeekly Market Outlook & Low Volatility Stock Suggestions - newser.com

Nov 19, 2025

Replimune Group Executives Sell Shares for Tax Obligations - TradingView

Nov 19, 2025

[Form 4] Replimune Group, Inc. Insider Trading Activity - Stock Titan

Nov 19, 2025

Why Replimune Group Inc. stock is a must watch in 2025July 2025 Levels & Weekly High Momentum Picks - newser.com

Nov 19, 2025

Smart tools for monitoring Replimune Group Inc.’s price actionWeekly Trade Summary & Accurate Entry and Exit Point Alerts - newser.com

Nov 19, 2025